AHG (Akso Health Group) 5-Year EBITDA Growth Rate: 59.90% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AHG Akso Health Group AHG
36 GF Score
Price $0.93
GF Value $0.39
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Akso Health Group 5-Year EBITDA Growth Rate?

Akso Health Group AHG -8.85% 36 5-Year EBITDA Growth Rate is 59.90% as of Mar. 2026. GuruFocus rates AHG with a GF Score™ of 36/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Akso Health Group's EBITDA per Share for the six months ended in Mar. 2026 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 85.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 59.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Akso Health Group was 85.30% per year. The lowest was -11.80% per year. And the median was 38.80% per year.


Akso Health Group  (NAS:AHG) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Akso Health Group 5-Year EBITDA Growth Rate Related Terms


AHG vs ACH, FOCL, YI: 5-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, Akso Health Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akso Health Group 5-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Akso Health Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Akso Health Group's 5-Year EBITDA Growth Rate falls into.


AHG
36GF Score
Akso Health Group AHG
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akso Health Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 59.90% mean?
Akso Health Group (AHG) has a 5-Year EBITDA Growth Rate of 59.90% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Akso Health Group and its competitors.
Is Akso Health Group's 5-Year EBITDA Growth Rate too high?
Akso Health Group's current 5-Year EBITDA Growth Rate is 59.90%. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's 5-Year EBITDA Growth Rate compare to ACH and FOCL?
Akso Health Group's 5-Year EBITDA Growth Rate of 59.90% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Distribution company?
A good 5-Year EBITDA Growth Rate depends on the Medical Distribution industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Akso Health Group and its competitors. Akso Health Group's current 5-Year EBITDA Growth Rate is 59.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $0.93 — trading 138.4% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 59.90%. Akso Health Group's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Akso Health Group (AHG), the current 5-Year EBITDA Growth Rate is 59.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akso Health Group (AHG) Overvalued in 2026?

Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued. The current stock price of $0.93 is trading 138.4% above its estimated GF Value™ of $0.39. GuruFocus considers Akso Health Group to be Significantly Overvalued.

Key valuation signals for AHG:

  • 5-Year EBITDA Growth Rate: 59.90%
  • GF Value™: $0.39 vs. price of $0.93 (138.4% above fair value)
  • GF Score™: 36/100 with 3 warning signs

No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akso Health Group Business Description

Other Exchanges 8HX:Germany
Address No. 44, Moscow Road, Qianwan Bonded Port Area, Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, Qingdao Pilot Free Trade Zone, Shandong, CHN
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score

Get the complete analysis for AHG

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price
$0.39
GF Value